Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC

May 15th 2024

As investigators parse out the mechanism of action of nadofaragene firadenovec, additional gene therapies are under development in BCG-unresponsive NMIBC.

Applying the Heterogeneous Approach From NSCLC to SCLC

May 14th 2024

Anne Chiang, MD, PhD, discusses understanding the heterogeneity of SCLC to determine which patients will respond to targeted therapy.

The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma

May 13th 2024

Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.

AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward

May 6th 2024

Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

May 2nd 2024

Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.

Final USPSTF Recommendation Statement Advises Women Begin Receiving Mammograms at 40 Years Old

May 1st 2024

The United States Preventive Services Task Force final breast cancer screening recommendation statement advises that women aged 40 begin biennial screening.

Examining Potential Markers of Osteosarcoma Stem Cells Is at the Forefront of Research

April 30th 2024

R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with cancer stem cells.

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

April 25th 2024

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

Uveal Melanoma Immunogenomic Score Shows Predictive Potential

April 23rd 2024

Investigators examined 100 metastases and developed a Uveal Melanoma Immunogenomic Score to predict which patients will respond to immunotherapy.

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

April 19th 2024

R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting.

Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC

April 18th 2024

Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Personalized Dosimetry With Y-90 Glass Microspheres Shows Positive Activity in HCC

April 17th 2024

Etienne Garin, MD, PhD, details how the PROACTIF study was conducted and how Y-90 Glass Microspheres could fill an unmet need for patients with hepatocellular carcinoma.

Clinicians Turn Their Focus to pMMR Disease Following Immunotherapy’s Entrance Into dMMR Endometrial Cancer

April 16th 2024

Exploration continues for the use of immunotherapy in patients with mismatch repair–proficient endometrial cancer.

Orca-T May Be a Suitable Option Over PTCy-Based HSCT in Acute Leukemia and MDS

April 15th 2024

Orca-T demonstrated positive impacts on relapse-free survival and overall survival vs PTCy-based HSCT in acute leukemias and myelodysplastic syndrome.

When Does the PD-1 Inhibitor Come Before the Hedgehog Inhibitor for Neoadjuvant Basal Cell Carcinoma?

April 11th 2024

Experts discuss when to use the PD-1 inhibitor cemiplimab vs the hedgehog inhibitor vismodegib as neoadjuvant treatment in non-melanoma skin cancers.

The New Frontier With Integrative Oncology: Shooting for the Stars

April 11th 2024

Richard T. Lee, MD, and Edward S. Kim, MD, MBA, discuss the benefits of integrative oncology and exploring integrative approaches at the Cherng Family Center for Integrative Oncology at City of Hope.

PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC

April 10th 2024

FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.

Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti–PD-1 Therapy in High-Risk Resectable Melanoma

April 9th 2024

Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.

Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC

April 8th 2024

Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.

Cadonilimab Plus Oxaliplatin and Capecitabine Offers Survival Benefit in Gastric/GEJ Cancer

April 7th 2024

Cadonilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.